Drugs / Bromelain
Bromelain
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05687760 | Feb 2023 | — | Cairo University | Unknown | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT06505759 | Jul 2024 → Jul 2025 overdue | periodontal disorder | Krishnadevaraya College of Dental Sciences & Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06775392 | Jan → Aug 2024 | periodontal disorder | Krishnadevaraya College of Dental Sciences & Hospital | Completed | No outcome recorded |
| Phase 1 | NCT05220605 | Jul → Aug 2022 | acute respiratory distress syndrome, pneumonia | Mucpharm Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04982146 | Sep 2021 → May 2022 | pseudomyxoma peritonei | Maimónides Biomedical Research Institute of Córdoba | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05258682 | May → Sep 2022 | COVID-19, acute respiratory distress syndrome, pneumonia | Mucpharm Pty Ltd | Unknown | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06981767 | Feb → Jul 2026 overdue | lichen planus, oral | Cairo University | Recruiting | No outcome recorded |
| Phase 2 | NCT06993337 | Jun 2025 → May 2026 overdue | aphthous stomatitis | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03976973 | May 2022 → Nov 2023 | pseudomyxoma peritonei | Mucpharm Pty Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT04512482 | Jun → Jul 2018 | smooth surface dental caries | Indiana University | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07088042 | Sep 2024 → Feb 2025 | pulpitis | Ain Shams University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06298383 | Jun 2025 → Feb 2026 | pulpitis | Cairo University | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04040660 | — | — | MediWound Ltd | Approved for marketing | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02340845 Comparator | May 2014 → Jan 2015 | cancer | Oeyama-Moto Cancer Research Foundation | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05681312 Comparator | May → Sep 2024 | — | University of Baghdad | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bromelain | “The API is a concentrate of proteolytic enzymes enriched in Bromelain extracted from the stem of Ananas comosus (pineapple plant)” NCT04040660 ↗13“Bromelain is a natural proteolytic enzyme derived from pineapple, recognized for its broad range of pharmacological properties.” NCT06993337 ↗ “Tibrolin is a fixed dose combination of(Trypsin 48 mg, Bromelain 90 mg) and a bioflavonoid (Rutoside 100 mg)” NCT05681312 ↗ “Received Limitless Allzyme Max® Trypsin/Chymotrypsin/Bromelain(15 microkatal/42microkatal/240 GDU)” NCT07088042 ↗ “Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei” NCT04982146 ↗ “BromAc is a product that combines two existing products (Bromelain and Acetylcysteine)” NCT05220605 ↗ |
| Known as | Bromelains | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05258682 ↗ |
| Known as | Comosain | “Bromelain (Comosain) extract, derived from the stem and fruit of Ananas Comosus will be administered orally each day.” NCT02340845 ↗ |
| Modality | Protein / enzyme biologic | “concentrate of proteolytic enzymes” NCT04040660 ↗ |
| Route | Oral | “administered orally” NCT02340845 ↗ |